Is a 12-month interval more effective than an 18-month interval between IV Zoledronate 5 mg treatments for osteoporosis in men or postmenopausal women?
Abstract
There is no direct evidence comparing 12- and 18-month dosing intervals for Zoledronate in osteoporosis treatment, with the 12-month schedule being the current standard practice.
Fields of Study & Subjects
Bone health and osteoporosis research
Bone health and treatments
Menopause: Health Impacts and Treatments
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 27 January 2026